We're Balanced Pharma.
We're improving lives
by improving
patient comfort.
Current Product Pipeline
Target product profiles
BPI-001
BPI-001
Best-in-class local dental anesthetic
BPI-001 (“Libracaine”) is a best-in-class, injectable anesthetic for dental procedures that is significantly less painful, faster-acting, and more likely to get patients numb than the current drugs.
- Less painful
- Faster-acting
- More reliable
- Same safety profile
- Same shelf-life
- Same cartridge
BPI-004
BPI-004
Best-in-class post-surgical analgesic
BPI-004 (“Enduracaine”) is a non-opioid, single-dose injectable local analgesic that provides up to three days of pain relief following surgical procedures.
- Non-opioid
- Multi-day pain relief
- Low toxicity
- Low motor impairment
Oral & maxillofacial surgery, orthopedic surgery, general surgery, podiatric surgery, gynecological surgery, CT surgery
View Helping End the Opioid Crisis
View the 40-second video: Helping End the Opioid Crisis
Recent Press
More Evidence for Buffered Anesthetic
Featured in Dental Economics | August 30, 2026
New research shows that buffered articaine can significantly reduce injection pain and speed the onset of anesthesia compared to nonbuffered formulations. See why buffered...
Buffered Anesthetic: The New Standard of Care
Featured in Dental Economics | April 10, 2026
Buffered local anesthesia cuts injection pain and acts faster. With new affordable technology, dentists can enhance patient comfort while meeting legal responsibilities, setting a new standard of care...
Buffered Anesthesia Rivalry Heats up in Dental Industry
Featured in Dr. Bicuspid | October 16, 2025
When 58% of patients say the injection is the worst part of the dental experience, it's time someone did something about it, and that's exactly what is happening right now...
Septodont Invests in Balanced Pharma, Joins Board
Featured in Dentistry Today | January 20, 2025
Septodont, the dominant global leader in dental anesthetics, has made a strategic investment in Balanced Pharma Inc. (“BPI”) as part of an institutional funding round, and Septodont COO Atif Zia has...
Balanced Pharma Analgesic Aims to Lower Opioid Use
Featured in Dentistry Today | November 12, 2024
Balanced Pharma Incorporated (BPI) has announced the acquisition of rights to a promising new non-opioid injectable post-surgical pain relief drug...
Dr. Howard S. Glazer Joins Balanced Pharma
Featured in Conexiant | March 12, 2024
Leading dental educator predicts huge impact for patients, providers. Howard S. Glazer, DDS, FAGD has joined Balanced Pharma’s Scientific Advisory Board. Dr. Glazer, an award-winning, leading voice in dental education...
